Acadian Asset Management LLC Has $842,000 Holdings in Athira Pharma, Inc. (NASDAQ:ATHA)

Acadian Asset Management LLC lowered its stake in shares of Athira Pharma, Inc. (NASDAQ:ATHA) by 42.2% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 318,090 shares of the company’s stock after selling 231,848 shares during the period. Acadian Asset Management LLC owned approximately 0.83% of Athira Pharma worth $842,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Private Advisor Group LLC bought a new position in Athira Pharma during the fourth quarter valued at about $32,000. Rothschild Investment LLC purchased a new stake in shares of Athira Pharma in the second quarter worth $34,000. Mirador Capital Partners LP bought a new stake in Athira Pharma during the first quarter valued at $57,000. Forefront Analytics LLC grew its position in Athira Pharma by 43.0% during the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock worth $72,000 after buying an additional 8,955 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in Athira Pharma by 84.1% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company’s stock worth $1,363,000 after acquiring an additional 227,278 shares during the last quarter. 57.12% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Athira Pharma

In related news, Director Kelly A. Romano acquired 15,000 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was acquired at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the acquisition, the director now owns 53,315 shares of the company’s stock, valued at $120,491.90. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Athira Pharma news, Director Kelly A. Romano acquired 27,400 shares of the business’s stock in a transaction on Monday, June 24th. The shares were acquired at an average price of $2.42 per share, for a total transaction of $66,308.00. Following the completion of the acquisition, the director now owns 80,715 shares in the company, valued at $195,330.30. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Kelly A. Romano bought 15,000 shares of the stock in a transaction dated Friday, June 21st. The shares were acquired at an average price of $2.26 per share, with a total value of $33,900.00. Following the completion of the acquisition, the director now directly owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The disclosure for this purchase can be found here. Insiders sold a total of 8,829 shares of company stock worth $5,033 over the last quarter. 19.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. BTIG Research lowered shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. JMP Securities cut Athira Pharma from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 4th. Finally, Rodman & Renshaw cut Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th.

Athira Pharma Stock Performance

NASDAQ:ATHA opened at $0.51 on Tuesday. Athira Pharma, Inc. has a fifty-two week low of $0.46 and a fifty-two week high of $4.30. The firm has a market cap of $19.39 million, a PE ratio of -0.17 and a beta of 2.90. The business has a 50 day moving average price of $2.72 and a 200-day moving average price of $2.59.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. Research analysts predict that Athira Pharma, Inc. will post -2.56 EPS for the current year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.